2,463
Participants
Start Date
April 24, 2021
Primary Completion Date
May 13, 2026
Study Completion Date
May 13, 2026
zalunfiban
zalunfiban is a novel small molecule inhibitor of the platelet αIIbβ3 receptor specifically designed for first medical contact therapy of ST-elevation myocardial infarction (STEMI).
Placebo
A placebo will be prepared to those subjects assigned to placebo. Less than 1 mL (depending on subject's weight) will be administered by subcutaneous injection.
"Instituto Nacional de Cardiologia Ignacio Chavez", Mexico City
Corewell Health William Beaumont University Hospital, Royal Oak
Washington University, St Louis
UT Southwestern Medical Center, Dallas
Baylor College of Medicine, Houston
Hospital Ambroise Pare, Boulogne-Billancourt
Providence Alaska Medical Center, Anchorage
University of Alberta, Edmonton
St. Anne's University hospital, Brno
University Hospital Brno, Brno
European Hosital de Paris - GVM Care & Research (La Roseraie), Aubervilliers
Henri Mondor University Hospital, Créteil
Grenoble Alpes University Hospital, Grenoble
University Hospital of Marseille - La Timone Hospital, Marseille
André Grégoire Hospital - GHT GPNE, Montreuil
Bichat-Claude Bernard Hospital, Paris
Hôpital Cochin, Paris
Lariboisière Hospital AP-HP, Paris
University Hospital De La Pitié-Salpêtrière, Paris
Regional University Hospital of Rennes - Hospital Ponchaillou, Rennes
Semmelweis University Heart and Vascular Center, Budapest
Bacs-Kiskun County Teaching Hospital, Kecskemét
Zuyderland MC, Heerlen
Jeroen Bosch Ziekenhuis, 's-Hertogenbosch
Amsterdam UMC, locatie AMC, Amsterdam
Amsterdam UMC, Amsterdam
Rijnstate Arnhem, Arnhem
Tergooi Blaricum, Blaricum
Amphia Ziekenhuis, Breda
Slingeland Ziekenhuis, Doetinchem
Ziekenhuis Gelderse Vallei, Ede
Medisch Spectrum Twente, Enschede
Leiden University Medical Center, Leiden
Maastricht UMC, Maastricht
ETZ TweeSteden, Tilburg
UMC Utrecht, Utrecht
Viecuri Medisch Centrum, Venlo
Isala, Zwolle
"Emergency Clinical Hospital Bagdasar-Arseni, Bucharest", Bucharest
Emergency University Hospital Bucharest, Bucharest
"Institute of Cardiovascular Diseases Prof. George I.M. Georgescu Iasi", Iași
Emergency Clinical County Hospital Targu-Mures, Târgu Mureş
Institute for Cardiovascular Diseases Timisoara, Timișoara
University of Debrecen, Debrecen
St. Antonius Ziekenhuis, Nieuwegein
Lead Sponsor
CeleCor Therapeutics
INDUSTRY